J

Johnson & Johnson

Makes prescription drugs and medical devices

Technology Product Lead - Automation Integration

Full-TimePosted on 10/23/2026Deadline 11/6/26
€79.8k - €137.8k+ Annual bonus + Sales commissions
Mid
Bachelor's, Master's
Spring House, PA, USA+1 moreMore locations: Beerse, Belgium
HybridHybrid work in Beerse; a separate opportunity is located in Spring House, Pennsylvania.
ProductTechnical Product Management

About the job

Requirements
  • A bachelor's degree in Computer Science, Information Technology, Engineering, Life Sciences, or a related field is required; an equivalent combination of education and relevant experience will be considered.
  • Experience in product management, project leadership, solution delivery, systems integration, automation technologies, or related disciplines.
  • Experience leading complex cross-functional technology initiatives involving multiple stakeholders and technology platforms.
  • Demonstrated experience translating business requirements and operational needs into technical solutions and delivery plans.
  • Strong understanding of enterprise integration principles, including application programming interfaces (APIs), middleware, messaging, workflow orchestration, and event-driven architectures.
  • Experience integrating applications, platforms, instruments, or automated systems within complex enterprise environments.
  • Experience working within Agile, product-oriented, or hybrid delivery approaches.
  • Demonstrated ability to lead initiatives and influence stakeholders without direct management authority.
  • Experience using artificial intelligence tools and digital assistants to accelerate analysis, synthesize information, develop content, and support decision-making.
  • Strong communication, presentation, analytical, problem-solving, and decision-making skills.
  • Ability to manage priorities, risks, dependencies, and competing stakeholder expectations in a fast-paced environment.
Responsibilities
  • Lead the successful delivery of one or more automation integration initiatives within the Business Technology Automation Integration product portfolio.
  • Define initiative scope, objectives, requirements, and success criteria in partnership with scientific, operational, and business stakeholders.
  • Develop delivery plans and coordinate execution activities across multiple teams and technology platforms.
  • Manage priorities, risks, dependencies, and stakeholder expectations to ensure successful outcomes.
  • Ensure delivered capabilities achieve measurable business value and support scientific operations.
  • Partner with scientific, operational, and business stakeholders to understand automation requirements and workflow needs.
  • Translate complex business processes and operational challenges into scalable technology solutions.
  • Serve as the primary technology contact for assigned automation integration initiatives.
  • Facilitate discussions between stakeholders, software engineers, automation specialists, and architecture teams to ensure alignment on requirements, priorities, and outcomes.
  • Build trusted working relationships that promote effective collaboration across scientific and technology organizations.
  • Ensure automation solutions align with the Business Technology Automation Integration product strategy, standards, architectural principles, and approved technology patterns.
  • Promote adoption of shared integration services, APIs, workflow orchestration capabilities, and reusable architecture components.
  • Support the implementation of modern integration approaches, including API-based and event-driven architectures.
  • Identify opportunities to improve automation connectivity, workflow accessibility, system interoperability, and operational efficiency.
  • Advocate for reuse of existing capabilities before introducing new solutions or technologies.
  • Identify opportunities to standardize and simplify integration approaches across automation environments.
  • Contribute to the evolution of integration capabilities, technology patterns, and delivery practices within the Automation Integration product space.
  • Support the evaluation of new technologies and approaches that can enhance automation, integration, and workflow enablement capabilities.
  • Promote continuous improvement, knowledge sharing, and adoption of best practices across delivery teams.
Desired Qualifications
  • A master's degree or equivalent experience in Business, Engineering, Computer Science, Life Sciences, or a related field.
  • Experience supporting pharmaceutical, biotechnology, healthcare, research, or scientific organizations.
  • Knowledge of drug discovery, laboratory operations, screening, profiling, sample management, or other scientific workflows.
  • Experience supporting laboratory automation, robotics, scientific instruments, or digital laboratory initiatives.
  • Familiarity with automation vendors, platforms, enterprise integration technologies, cloud technologies, security, and data governance principles.
  • Experience supporting platform products or shared technology services.
  • Experience coordinating vendor relationships and strategic partnerships.
  • Demonstrated success driving standardization, platform reuse, and technology modernization initiatives.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.